LTS Lohmann Therapie-Systeme AG
25.06.2025 - 14:00
Andernach / Montreal (ots) - LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic ...
To the press release of LTS Lohmann Therapie-Systeme AG14.01.2025 - 12:00
Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the ...
To the press release of LTS Lohmann Therapie-Systeme AG28.02.2024 - 13:00
Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, announced today that its customer Coherus BioSciences, Inc (“Coherus”) has launched its UDENYCA® on-body injector (OBI) utilizing the ...
To the press release of LTS Lohmann Therapie-Systeme AG19.12.2023 - 13:00
Andernach (ots) - LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The purpose of the grant is to support the development of microneedle array patches (MAP) for ...
To the press release of LTS Lohmann Therapie-Systeme AG06.12.2023 - 16:00
Andernach (ots) - LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The grant will support new formulation methods for mRNA, such as dissolvable microneedle array ...
To the press release of LTS Lohmann Therapie-Systeme AG 
